John Poyhonen - 13 Jul 2021 Form 4 Insider Report for HERON THERAPEUTICS, INC. /DE/ (HRTX)

Role: President & CCO
Signature: /s/ Lisa Peraza Attorney-in-fact for John Poyhonen
Issuer symbol: HRTX
Transactions as of: 13 Jul 2021
Net transactions value: +$7,658
Form type: 4
Filing time: 15 Jul 2021, 16:49:39 UTC
Next filing: 15 Oct 2021
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	HRTX	Common Stock	Other	$13,494	+971	+4.8%	$13.90	21,385	30 Apr 2021	Direct	F1
transaction	HRTX	Common Stock	Options Exercise		+1,250	+5.8%		22,635	13 Jul 2021	Direct	F2
transaction	HRTX	Common Stock	Tax liability	$5,837	-433	-1.9%	$13.48	22,202	13 Jul 2021	Direct	F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	HRTX	Restricted Stock Units	Options Exercise	$0	-1,250	-7.1%	$0.000000	16,250	13 Jul 2021	Common Stock	1,250		Direct	F2, F4

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents shares acquired under the Heron Therapeutics, Inc. 1997 Employee Stock Purchase Plan on April 30, 2021.
F2	Restricted stock units convert into common stock on a one-for-one basis.
F3	Represents the withholding by the Company of certain of the vested shares of restricted stock to satisfy the minimum statutory tax obligations applicable to such transactions.
F4	The restricted stock units vest in 16 equal quarterly installments beginning three months after the date of grant (10/13/2020).